Details for New Drug Application (NDA): 202912
✉ Email this page to a colleague
The generic ingredient in ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE is abacavir sulfate; lamivudine; zidovudine. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the abacavir sulfate; lamivudine; zidovudine profile page.
Summary for 202912
Tradename: | ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE |
Applicant: | Lupin Ltd |
Ingredient: | abacavir sulfate; lamivudine; zidovudine |
Patents: | 0 |
Pharmacology for NDA: 202912
Mechanism of Action | Nucleoside Reverse Transcriptase Inhibitors |
Suppliers and Packaging for NDA: 202912
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE | abacavir sulfate; lamivudine; zidovudine | TABLET;ORAL | 202912 | ANDA | Lupin Pharmaceuticals, Inc. | 68180-286 | 68180-286-01 | 1 BOTTLE in 1 CARTON (68180-286-01) > 100 TABLET in 1 BOTTLE |
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE | abacavir sulfate; lamivudine; zidovudine | TABLET;ORAL | 202912 | ANDA | Lupin Pharmaceuticals, Inc. | 68180-286 | 68180-286-02 | 1 BOTTLE in 1 CARTON (68180-286-02) > 500 TABLET in 1 BOTTLE |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 300MG BASE;150MG;300MG | ||||
Approval Date: | Dec 5, 2013 | TE: | AB | RLD: | No |
Complete Access Available with Subscription